Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GSK's Lynavoy (linerixibat) wins FDA approval for cholestatic pruritus in primary biliary cholangitis patients
Small molecule, liver disease, IBAT inhibitor, primary biliary cholangitis, cholestatic pruritus - Read more

Novo Nordisk's Wegovy HD (semaglutide) wins FDA approval for obesity treatment under priority voucher program
Small molecule, metabolic, GLP-1 agonist, obesity, type 2 diabetes - Read more

Rhythm Pharmaceuticals' IMCIVREE (setmelanotide) wins FDA approval expansion for acquired hypothalamic obesity treatment
Small molecule, metabolic, MC4R agonist, hypothalamic obesity, rare disease - Read more

Fauna Bio, Eli Lilly achieve obesity target milestone using hibernation-inspired AI platform, triggers payment
Research collaboration, AI/ML, drug discovery, milestone payments - Read more

Collegium Pharmaceutical acquires ADHD drug Azstarys from Corium Therapeutics for $650M upfront payment
Central nervous system stimulant, neurological, strategic, major transaction - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Pfizer's Talzenna (talazoparib) plus Xtandi shows Ph3 success in metastatic castration-sensitive prostate cancer
Small molecule, cancer, PARP inhibitor, prostate cancer, combination therapy, DNA damage repair - Read more

AlzeCure Pharma presents new preclinical data for NeuroRestore ACD856 targeting Trk receptors for Alzheimer's disease
Small molecule, neurological, TRK receptor modulator, Alzheimer's disease, depression, neuroprotection - Read more

Arvinas reports positive Ph1 results for ARV-102 targeting LRRK2 protein in Parkinson's disease patients
Small molecule, neurological, PROTAC degrader, Parkinson's disease, LRRK2 target - Read more

Eli Lilly's retatrutide (retatrutide) hits Ph3 goals in Type 2 diabetes, targeting GLP-1/GIP/glucagon hormones
Protein therapy, metabolic, GLP-1 receptor agonist, Type 2 diabetes, triple hormone receptor agonist, obesity - Read more

Kalohexis emerges from Endevica Bio to develop melanocortin-targeted therapeutics for obesity and metabolic diseases
Peptide, metabolic disease, strategic, operational - Read more

Congruence Therapeutics raises $39.5M financing to advance small molecule correctors pipeline
Small molecule, protein misfolding, clinical-stage, AI/ML platform, rare disease, neurological - Read more

UW Institute for Protein Design receives $7M grant, AI-enabled enzyme design
Protein design, AI-driven, enzyme development, platform technology - Read more

Axplora invests $60M to expand Italian API manufacturing facility, boosting high-potency drug production capacity
Antibody-drug conjugate, oncology, operational, major transaction - Read more

AstraZeneca to build Shanghai cell therapy manufacturing facility, first multinational with end-to-end capabilities in China
Cell therapy, oncology, strategic, major investment, operational - Read more

Syneos Health acquires Chinese CRO Bestudy to strengthen position in rapidly growing Asian market
Strategic, operational, major transaction, competitive - Read more

Maryland bill requires pharma transparency in disease awareness campaigns, mandating registration and drug connection disclosures
Regulatory, strategic, operational, transparency - Read more

Sarepta Therapeutics seeks FDA traditional approval for Amondys 45 and Vyondys 53 targeting Duchenne muscular dystrophy
Antisense oligonucleotide, neurological, Duchenne muscular dystrophy, exon skipping, accelerated approval - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Genentech halts Ph2 trial of flizasertib (GDC-8264) RIPK1 inhibitor for acute kidney injury after futility analysis
Small molecule, cardiovascular, RIPK1 inhibitor, acute kidney injury, kinase inhibitor - Read more

Gossamer Bio cuts 48% of workforce following Phase 3 seralutinib failure in pulmonary arterial hypertension
Small molecule, cardiovascular, cost reduction, operational, financial - Read more

Pfizer discontinues PF-08046031 Ph1 trial targeting CD228 for advanced melanoma and solid tumors
Antibody-drug conjugate, cancer, solid tumors, melanoma, CD228 target, pipeline discontinuation - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here